1、 2012 10 11 19 90 2006 2011 10 3 FDA 1 2 3 4 3 3 EPS PE PEG 11 12E 13E 14E 11 12E 13E 14E 52.56 1.18 1.39 1.75 2.21 42 38 30 24 1.4 28.00 0.82 0.85 1.06 1.30 34 33 26 22 1.2 2012 10 9 021-68763527 S1010510120046 010-60836718 S1010512090002 1. . 2012-08-01 2. 600535 20 1 2- 0 4-17 3. 002603 2011-10
2、-18 1 1 2 5 5 9 10 11 18 ” 22 22 24 35 36 1 20022011 . 1 2 2 . 2 3 2011 10 2 4 3 5 2018 3 6 . 5 7 6 8 7 9 . 8 10 8 11 . 9 12 . 10 13 . 10 14 11 15 12 16 . 12 17 . 13 18 . 14 19 15 20 . 16 21 . 16 22 . 17 23 ASCO 2012 . 18 24 . 19 25 . 19 26 . 20 27 . 21 28 . 21 29 . 23 30 . 24 31 . 25 32 . 26 33 . 2
3、6 34 . 27 35 . 28 36 29 37 . 29 38 . 30 39 . 31 40 FDA III 31 41 2012 . 32 42 . 33 43 . 34 44 . 35 45 . 36 1 37 2 38 2012 10 11 1 1991 10 10 2011 3 10 8 7 1896 SIX 18 2 1 20022011 2012 10 11 2 2 2 Bloomberg 5 2011 10 3 2011 10 IMS health 2012 10 11 3 4 Bloomberg 2011 646 8.2% EvaluatePharma 2018 10
4、41 11.1% 20112018 CAGR 8.3% 2018 276 26.5% 5 2018 EvaluatePharma 2012 10 11 4 2012 10 11 5 18501910 1765 18 19 19 6 Wikipedia 1 2 3 2012 10 11 6 19 70 1997 David Sackett 7 Wikipedia 1990 1994 4S 10 WOSCOPS CARE AFCAPS/TexCAPS LIPID HPS LDL-C 2012 10 11 7 8 PubMed The Cochrane Library 2004 100 2006 130 10 900 2012 10 11 8 9 Pfizer PubMed The Cochrane Library 10 Pfizer 2012 10 11 9 FDA 2001 FDA CML FDA FDA 6 2007 553 CML 0% 364 6 88% CML 5 48% 11 Boston Healthcare Novartis 2012 10 11 10 12 Boston Healthcare Roche 13 Boston Healthcare Merck
